Commentary: The small-molecule ‘penalty’ is a threat to Mass. biotech sector

The Inflation Reduction Act inadvertently introduced a change in drug-development incentives that could result in distorted decisions about which treatments get developed.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks